These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25624918)

  • 21. Fascin and EMMPRIN expression in primary mucinous tumors of ovary: a tissue microarray study.
    Alici O; Kefeli M; Yildiz L; Baris S; Karagoz F; Kandemir B
    Pathol Res Pract; 2014 Dec; 210(12):934-8. PubMed ID: 25155376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression.
    Wu S; Boyer CM; Whitaker RS; Berchuck A; Wiener JR; Weinberg JB; Bast RC
    Cancer Res; 1993 Apr; 53(8):1939-44. PubMed ID: 8385577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer.
    Kusuda T; Shigemasa K; Arihiro K; Fujii T; Nagai N; Ohama K
    Oncol Rep; 2005 Jun; 13(6):1153-8. PubMed ID: 15870936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of alpha-smooth muscle actin in benign or malignant ovarian tumors.
    Kobayashi H; Tsuruchi N; Sugihara K; Kaku T; Saito T; Kamura T; Tsukamoto N; Nakano H; Taniguchi S
    Gynecol Oncol; 1993 Mar; 48(3):308-13. PubMed ID: 8462899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional expression of TWEAK and the receptor Fn14 in human malignant ovarian tumors: possible implication for ovarian tumor intervention.
    Gu L; Dai L; Cao C; Zhu J; Ding C; Xu HB; Qiu L; Di W
    PLoS One; 2013; 8(3):e57436. PubMed ID: 23469193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum cytokines and CXCR2: potential tumour markers in ovarian neoplasms.
    Micheli DC; Jammal MP; Martins-Filho A; Côrtes JRXM; Souza CN; Nomelini RS; Murta EFC; Tavares-Murta BM
    Biomarkers; 2020 Sep; 25(6):474-482. PubMed ID: 32544350
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serological and immunohistochemical biomarkers for discrimination between benign and malignant ovarian tumors.
    Dijmărescu AL; Gheorman V; Manolea MM; Vrabie SC; Săndulescu MS; Siloşi CA; Siloşi I; Radu M; Popescu-Drigă MV; Novac MB; Pădureanu V; Istrate-Ofiţeru AM; Boldeanu L
    Rom J Morphol Embryol; 2019; 60(4):1163-1174. PubMed ID: 32239091
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of cytokines and inducible nitric oxide synthase expression with prognostic factors in ovarian cancer.
    Martins Filho A; Jammal MP; Côbo Ede C; Silveira TP; Adad SJ; Murta EF; Nomelini RS
    Immunol Lett; 2014; 158(1-2):195-9. PubMed ID: 24447864
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proliferation and maturation of intratumoral blood vessels in women with malignant ovarian tumors assessed with cancer stem cells marker nestin and platelet derived growth factor PDGF-B.
    Czekierdowska S; Stachowicz N; Chróściel M; Czekierdowski A
    Ginekol Pol; 2017; 88(3):120-128. PubMed ID: 28397199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelial ovarian tumors: Clinicopathological correlation and immunohistochemical study.
    Naik PS; Deshmukh S; Khandeparkar SG; Joshi A; Babanagare S; Potdar J; Risbud NS
    J Midlife Health; 2015; 6(4):178-83. PubMed ID: 26903759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.
    van der Zee AG; de Cuyper EM; Limburg PC; de Bruijn HW; Hollema H; Bijzet J; Krans M; de Vries EG
    Cancer; 1995 Feb; 75(4):1004-9. PubMed ID: 7842401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
    Gursan N; Sipal S; Calik M; Gundogdu C
    Eurasian J Med; 2009 Apr; 41(1):10-4. PubMed ID: 25610057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ovarian cancer-induced immunosuppression: relationship to tumor necrosis factor-alpha (TNF-alpha) release from ovarian tissue.
    Hassan MI; Kassim SK; Saeda L; Laban M; Khalifa A
    Anticancer Res; 1999; 19(6C):5657-62. PubMed ID: 10697636
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical analysis of 23 cases with simultaneous double primary gynecological malignant tumors].
    He Y; Wang Y; Ji C; Liu Y; Wu YM
    Zhonghua Fu Chan Ke Za Zhi; 2022 May; 57(5):352-360. PubMed ID: 35658326
    [No Abstract]   [Full Text] [Related]  

  • 35. Peritoneal fluid cytokines and the differential diagnosis of benign and malignant ovarian tumors and residual/recurrent disease examination.
    Chechlinska M; Kaminska J; Markowska J; Kramar A; Steffen J
    Int J Biol Markers; 2007; 22(3):172-80. PubMed ID: 17922459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ascites as a predictor of ovarian malignancy.
    Shen-Gunther J; Mannel RS
    Gynecol Oncol; 2002 Oct; 87(1):77-83. PubMed ID: 12468346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Type IV collagen and CD44v6 expression in benign, malignant primary and metastatic ovarian tumors: correlation with Ki-67 and p53 immunoreactivity.
    Bar JK; Grelewski P; Popiela A; Noga L; Rabczyñski J
    Gynecol Oncol; 2004 Oct; 95(1):23-31. PubMed ID: 15385106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytokines in gynecological cancer.
    Sarandakou A; Phocas I; Sikiotis K; Rizos D; Botsis D; Kalambokis K; Trakakis E; Chryssikopoulos A
    Anticancer Res; 1997; 17(5B):3835-9. PubMed ID: 9427789
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Preoperative Analysis of CA-I25 and its Relation with Histopathological Study in Ovarian Tumours.
    Nazneen T; Begum SA; Mahmud T; Khatoon F; Islam F; Amatullah M
    Mymensingh Med J; 2021 Apr; 30(2):402-409. PubMed ID: 33830120
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunohistochemistry with apoptotic-antiapoptotic proteins (p53, p21, bax, bcl-2), c-kit, telomerase, and metallothionein as a diagnostic aid in benign, borderline, and malignant serous and mucinous ovarian tumors.
    Ozer H; Yenicesu G; Arici S; Cetin M; Tuncer E; Cetin A
    Diagn Pathol; 2012 Sep; 7():124. PubMed ID: 22995373
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.